This is directed to decrease the activity of tumour cell using single molecules such as everolimus, curcumin or in combination with other therapies [47,48,49], to decrease the resistance to chemotherapy by mTOR inhibition (e.g., temsirolimus) [50] and radiotherapy [51] and interestingly also to prevent oral cancer, by its use in human oral potentially malignant disorders (OPMD), where the use of molecules such as metformin, or other molecules decreased these premalignant lesions with decreased mTOR activity [24]. The gene discussed is MTOR; the disease is oculopharyngeal muscular dystrophy.